Companies › Day One Biopharmaceuticals
3 active drug programs in 7 registered trials: 3 Phase 2, 3 Phase 1, 1 Phase 3; Oncology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tovorafenib RAF serine/threonine protein kinase inhibitor | RAF1, BRAF, ARAF | Phase 3 | Low-grade Glioma; Craniopharyngioma, Child; Recurrent Langerhans Cell Histiocytosis; Hairy Cell Leukemia | May 2027 |
| Emiltatug Ledadotin (Emi-Le) unclear - code-named drug, mechanism not specified in registry text | – | Phase 1 | Triple Negative Breast Cancer | Feb 2027 |
| DAY301 PTK7-directed antibody-drug conjugate | PTK7 | Phase 1 | Advanced or Metastatic Solid Tumors | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05377996 | Emiltatug Ledadotin (Emi-Le) | Phase 1 | Triple Negative Breast Cancer | Oncology | Feb 2027 |
| NCT05465174 | Tovorafenib | Phase 2 | Craniopharyngioma, Child | Oncology | Mar 2027 |
| NCT04775485 | Tovorafenib | Phase 2 | Low-grade Glioma | Oncology | May 2027 |
| NCT05566795 | Tovorafenib | Phase 3 | Low-grade Glioma | Oncology | Jun 2027 |
| NCT06752681 | DAY301 | Phase 1 | Advanced or Metastatic Solid Tumors | Oncology | Dec 2027 |
| NCT05828069 | Tovorafenib | Phase 2 | Recurrent Langerhans Cell Histiocytosis | Oncology | Sep 2028 |
| NCT06965114 | Tovorafenib | Phase 1 | Hairy Cell Leukemia | Oncology | Mar 2030 |
Roche Ipsen Novartis Hanmi Pharmaceutical Company Pfizer Erasca Pierre Fabre Medicament Haisco Pharmaceutical Group Bayer Nested Therapeutics
Nuvalent InxMed (Shanghai) RayzeBio Shanghai Kechow Pharma Pierre Fabre Medicament
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.